Trial Profile
A Selective Frontline Cabazitaxel Therapeutic Pathway for Castration-Resistant Prostate Cancer With Integrated Biomarkers
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Cabazitaxel (Primary) ; Prednisone (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Biomarker; Therapeutic Use
- 21 Jan 2021 Status changed from completed to discontinued due to poor accrual of subjects onto study.
- 07 Aug 2019 Status changed from active, no longer recruiting to completed.
- 04 Dec 2018 Status changed from recruiting to active, no longer recruiting.